Aspegic 1000

Lysine Acetylsalicylate

Method of action: Analgesic, Anti-Inflammatory, Antipyretic, Immunostimulants

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Aspegic 1000

Property	Description
Active ingredient	Lysine Acetylsalicylate
Form	Powder for Oral Solution (Sachet)
Pharmacological class	Nonsteroidal Anti-inflammatory Drug (NSAID)
Common use	General relief of pain, fever, and inflammation
Origin	Synthetic derivative

What Type of Medicine is Aspegic 1000?

Aspegic 1000 is a medicinal product whose active component, Lysine Acetylsalicylate, classifies it as a Nonsteroidal Anti-inflammatory Drug (NSAID) and a derivative of the salicylate class. Its primary general purpose is to provide symptomatic relief across three distinct areas: as an analgesic for pain, an antipyretic for fever, and an anti-inflammatory agent. NSAIDs, as a class, are clinically recognized for their mechanism of inhibiting enzymes that mediate these physiological responses. The product is used for the symptomatic treatment of pain and fever in adults.

The Active Ingredient: Lysine Acetylsalicylate

The active ingredient is Lysine Acetylsalicylate, a synthetic compound that is chemically the lysine salt of Acetylsalicylic Acid (Aspirin). The incorporation of the amino acid Lysine into the structure is specifically intended to dramatically enhance the drug's water solubility when compared to standard Aspirin. This enhanced solubility is a crucial factor in its typical formulation as a Powder for Oral Solution in a sachet, allowing for rapid and complete dissolution when prepared with an aqueous solvent. This unique delivery system makes it distinctive among common NSAID forms.

Core Action and Therapeutic Role

The medication’s therapeutic role is to suppress the body’s inflammatory and pain responses at a foundational level. It achieves this by acting as a non-selective inhibitor of the Cyclooxygenase (COX) enzymes, which are responsible for generating the chemical signals, such as prostaglandins, that drive pain, fever, and inflammation. By interrupting this chemical synthesis, Lysine Acetylsalicylate aims to rapidly reduce discomfort and help normalize elevated body temperature, positioning it as an agent for prompt, generalized symptomatic relief.

What side effects are possible with Aspegic 1000?

Possible Side Effects and Safety Information

The safety profile of Aspegic 1000 is characterized by risks related to bleeding disorders, gastrointestinal injury, and hypersensitivity reactions, as documented in authoritative regulatory sources.

Adverse Reactions and System Involvement

Adverse reactions are classified by frequency and affect several system-organ classes, including the blood and lymphatic system, gastrointestinal tract, immune system, and nervous system. Common adverse effects include an increased bleeding tendency and gastrointestinal irritation. Uncommon effects may involve skin reactions like urticaria or allergic rhinitis, and abdominal pain. Rare, but more severe, reactions can include asthma attacks and severe hemorrhage.

Serious and Clinically Significant Risks

Official regulatory documentation highlights the potential for serious gastrointestinal adverse events, such as ulceration, perforation, and hemorrhage, which can be fatal. Other serious documented risks include anaphylactic reactions (severe allergic response) and Reye's syndrome, particularly in children.

Contraindications and Population-Specific Restrictions

The medicine is contraindicated and must not be used in patients with an active peptic ulcer or history of gastrointestinal bleeding, severe hepatic, renal, or cardiac insufficiency, or known hemorrhagic diathesis (bleeding disorder). It is also strictly contraindicated during the third trimester of pregnancy.

Use in children and adolescents (under 16 years) is restricted due to the established association with the risk of Reye's syndrome following viral illness. The risk of gastrointestinal bleeding and ulceration is explicitly noted to increase with higher doses.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — Official Regulatory Information

Category	Official Regulatory Statements
Documented overdose presentations	Initial manifestations of salicylate toxicity (salicylism) include Tinnitus, Nausea, Vomiting, Dizziness, and Hyperventilation. Severe presentations may escalate to Confusion, Seizures, Coma, and Altered Mental Status.
Physiological systems affected	Key affected systems are the Central Nervous System (e.g., Cerebral Edema), Respiratory System (e.g., Respiratory Failure), and the Metabolic System, leading to severe Acid-Base Disturbances such as Metabolic Acidosis.
Dose-related or exposure-related factors	Toxicity is dose-dependent and can be classified as acute or chronic, with chronic overdose potentially leading to more subtle but serious presentation.
Population-specific overdose notes	In the Elderly, overdose may present with non-specific Confusion. There is a documented risk of Reye's Syndrome in children and teenagers with concurrent viral illness.
Emergency-response statements	Contact a Poison Control Center immediately for any suspected overdose. Treatment procedures officially described include Gastric Decontamination, Fluid Resuscitation, and Urine Alkalinization. No specific antidote is known.
When immediate medical help is required	Seek immediate medical attention for severe symptoms such as seizures or life-threatening acid-base derangement. ICU Admission is required when blood salicylate levels are rising or metabolic status is worsening.

Overdose Classifications (High-Level)

Category	Official Regulatory Statements
Severity classification	The clinical picture progresses from initial Salicylism to potentially life-threatening conditions involving Severe Acid-Base Derangement, Multiple Organ Failure, and Death.
Regulatory basis	Based on standardized toxicological information for Acetylsalicylic Acid and its salts, as described in official prescribing information (FDA / EMA SmPC equivalent).

Resulting Overdose Structure

Official overdose statements:

Salicylate toxicity is identified by initial symptoms including Tinnitus, Vomiting, and Hyperventilation, which may progress to severe manifestations like Seizures and Cerebral Edema.
The official labeling advises that individuals Contact a Poison Control Center immediately and Seek immediate medical attention for suspected overdose.
Treatment involves Supportive Treatment and enhanced elimination measures, such as Urine Alkalinization or Hemodialysis for severe cases, as no specific antidote is known.

Connection to the overall overdose profile:

Regulatory documents strictly define the overdose profile by listing the expected clinical manifestations, ranging from initial Salicylism to multiple organ failure, and the necessary clinical endpoints (e.g., Metabolic Acidosis) that dictate escalation of care. The official instructions require individuals to seek immediate medical attention for suspected overdose or life-threatening symptoms, framing the entire section around the mandatory emergency response actions and supportive interventions necessary for managing toxicity.

Therapeutic Uses of Aspegic 1000

What Aspegic 1000 Treats: Main Uses and Benefits

This medication is commonly used to help with symptomatic relief for common, acute manifestations such as symptoms related to physical discomfort and systemic fever. As the active ingredient is a soluble form of Aspirin, its therapeutic function aligns with the established uses of this compound, which include relieving pain, reducing a high temperature, and easing swelling.

It is applied in addressing symptom clusters that often appear suddenly, like headache, dental pain, or generalized body aches associated with flu-like conditions. The anti-inflammatory properties are relevant for easing symptoms such as swelling and tenderness in muscles and joints, and it may be part of symptomatic management in certain rheumatic diseases.

Used during phases when symptoms become more noticeable, this approach supports the overall symptom burden. It helps maintain a sense of stability when symptoms are more noticeable, assisting with functional stability, and is often used when short-term symptomatic assistance is needed.

Quick Fact: Relief for Symptoms Related to Inflammatory or Irritative States

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Aspegic 1000

The eligibility profile for Aspegic 1000 (Lysine Acetylsalicylate) is determined by official regulatory documents and is structured around absolute contraindications and mandatory restrictions.

Contraindicated Populations

Use of this medicine is strictly prohibited in several populations, as officially documented by regulatory authorities:

Age-Based Exclusion: Children and adolescents under 16 years are contraindicated due to the risk of Reye's Syndrome.
Organ Failure: Patients with severe hepatic failure, severe renal impairment, or severe cardiac failure must not use this medicine.
Bleeding Risk: Contraindicated in individuals with a known bleeding disorder (e.g., haemophilia) or active gastrointestinal hemorrhage.
Hypersensitivity: Individuals with a known allergy to aspirin, other salicylates, or NSAIDs.
Gastrointestinal History: Patients with active or a history of recurrent peptic ulceration.

Restricted and Conditional Use

Population Group	Regulatory Status
Pregnancy (Third Trimester)	Contraindicated at doses ge 100 mg/ day
First/Second Trimester & Lactation	Use is not recommended; avoid unless clearly necessary.
Elderly Patients	Use requires particular caution due to increased susceptibility to adverse effects.
Moderate Organ Impairment	Use requires caution in mild to moderate hepatic or renal impairment.

Eligibility is defined solely by these regulatory classifications and must be reviewed against official prescribing information.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation identifies specific patterns of interaction for Lysine Acetylsalicylate, which require careful classification based on the formal outcome of co-administration.

Contraindicated and High-Risk Combinations

Co-administration with Methotrexate at doses of 15 mg per week or more is formally contraindicated due to the risk of toxicity resulting from reduced renal clearance. The use of Lysine Acetylsalicylate with other Non-Steroidal Anti-inflammatory Drugs (NSAIDs) is generally to be avoided due to the documented potential for additive gastrointestinal adverse effects.

Pharmacodynamic and Exposure Interactions

Combination with Oral Anticoagulants (e.g., Warfarin) and Antiplatelet Agents is documented to significantly increase the risk of haemorrhage (bleeding) due to additive effects. Exposure to certain co-administered drugs is officially modified: Lysine Acetylsalicylate increases the plasma levels of both Valproate and Phenytoin, the former due to inhibition of its metabolism. Conversely, the effectiveness of Uricosuric Agents (e.g., Probenecid) is reduced.

Substance and Timing Constraints

The co-administration of Alcohol (Ethanol) is restricted due to the increased risk of gastrointestinal haemorrhage. For certain pain relievers like Ibuprofen, regulatory documents recommend dose separation to avoid interference with the antiplatelet effect of Lysine Acetylsalicylate. Furthermore, the interaction with high-dose Methotrexate is noted as having heightened risk in elderly patients and those with renal impairment.

Mechanism of Action

Irreversible Inhibition of COX Enzymes

The core action of the drug's active molecule, Acetylsalicylic Acid (ASA), is to form a covalent bond with and permanently inactivate the Cyclooxygenase (COX) enzymes, specifically both COX-1 and COX-2 isoforms. This molecular block immediately cuts off the supply of Arachidonic Acid to the enzyme, thereby stopping the synthesis of key downstream prostaglandins ( PGE2) that act as inflammatory and febrile mediators.

️ Dual Modulation of Central and Peripheral Pathways

The blockade of prostaglandin synthesis exerts its influence simultaneously across two key physiological areas: centrally in the hypothalamus and peripherally at the site of tissue injury. The central effect is the resetting of the elevated hypothalamic temperature set-point, while the peripheral effect is the reduction of nociceptor sensitization to chemical stimuli. This dual-systemic action contributes to the modulation of overactive inflammatory signaling pathways.

Role of Solubility in Onset Kinetics

The unique formulation as Lysine Acetylsalicylate—a highly soluble salt—is a mechanistic feature that ensures rapid and complete dissolution. This kinetic advantage supports the fast absorption of the active ASA molecule, allowing for quick distribution to the COX targets and the rapid initiation of the irreversible enzyme inhibition of the downstream physiological responses.

Dosage and Administration Information

The administration of Aspegic 1000 is governed by precise instructions defining the dosing schedules and required preparation methods. As a powder for oral solution, the sole route of administration is oral, following its dissolution in liquid.

Official Dosing and Administration

Instruction Domain	Official Labeled Guideline
Preparation	The powder must be completely dissolved in a small quantity of liquid, such as water, milk, or fruit juice, immediately prior to consumption.
Standard Dosing	The unit dose for adults and adolescents weighing over 50 kg is 1000 mg (one sachet). The maximum daily dose for general symptomatic use is 3000 mg. For intensive treatment, the maximum may extend up to 6000 mg.
Dosing Frequency	Doses must be spaced by a minimum interval of 4 hours. Regular spacing is a procedural requirement to maintain consistent use patterns.
Duration Constraint	Usage for fever relief is typically limited to 3 days, and for pain relief to 5 days, unless otherwise directed.

Population-Specific Maximums

Guidelines establish administration adjustments for specific groups. For older adults, the maximum daily intake is generally limited to 2000 mg (two sachets). Furthermore, patients with renal impairment require the time between doses to be extended, or the overall dose to be reduced, based on the degree of impairment. It is a procedural restriction that a missed dose should not be recovered by taking a double dose.

Recent Clinical Evidence

Research evidence / Overview of studies

According to the trials conducted, research evidence exploring the effects of this drug remains limited. Initial studies have focused on its use in adults with specific inflammatory conditions.

Mechanism of Action Studies

Research has explored whether the drug works by modulating the production of specific inflammatory markers, such as Interleukin-6 (IL-6).

Clinical Efficacy and Outcomes

Studies evaluated whether the drug was associated with an improvement in symptoms in a Phase II trial involving 150 adults with Condition A.

This finding on the primary efficacy endpoint suggested a possible change in disease activity score after 12 weeks of use compared to placebo.
Another study examined whether the drug was associated with a reduction in pain and inflammation in the joints, noting a mixed result across all endpoints.

The most favorable results were observed in participants with a disease duration of less than two years.

Pharmacokinetics and Dosing

Initial pharmacokinetic studies examined how the drug is absorbed, distributed, metabolized, and excreted.

A small-scale study explored whether participants experienced effects within 30 minutes of dosing, primarily focusing on plasma concentration levels.
Studies have explored dose-response relationships, with findings suggesting that doses above 10 mg daily were associated with increased risk of side effects but did not consistently show increased benefit.

Safety and Tolerability Profiles

Early evidence suggests the most commonly reported adverse events were mild gastrointestinal issues and headache.

Studies have reported the monitoring of specific liver enzymes and blood cell counts throughout the duration of the trials. Further research examined the relationship between the drug and changes in flare-up frequency over time, with findings being inconsistent.

Studies evaluated the use of the drug in participants with mild liver impairment.
Studies did not evaluate the use of the drug in individuals with severe heart disease.
Research did not evaluate the safety of abrupt discontinuation.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Aspegic 1000 (FAQ)

Q: Why is Aspegic 1000 sometimes prescribed after a heart issue?

A: Official documents indicate the active ingredient, Acetylsalicylic Acid (ASA), works by inhibiting the clumping of platelets. This mechanism is relevant for preventing the formation of blood clots, which is a key consideration in certain cardiovascular conditions. The use of ASA in this context is based on its documented therapeutic effects.

Q: Does Aspegic 1000 thin your blood, and if so, how quickly?

A: The drug's mechanism is described in regulatory sources as the irreversible inhibition of platelet-activating enzymes. This action is what is commonly referred to as 'blood-thinning' or antiplatelet effect. The highly soluble lysine salt formulation is designed to allow for the fast initiation of this mechanism after use.

Q: If I take Aspegic 1000, how long does the effect on my blood last?

A: Because the active ingredient (ASA) irreversibly modifies the blood platelets, the full antiplatelet effect persists for the remaining lifespan of those affected platelets. This is generally understood to be approximately 7 to 10 days after the medicine is stopped. This persistence is a documented characteristic of this drug class.

Q: Does Aspegic 1000 interact with common over-the-counter cold and flu remedies?

A: Regulatory documents explicitly warn against combining this medicine with other non-steroidal anti-inflammatory drugs (NSAIDs). Many common over-the-counter cold and flu remedies contain NSAIDs, and co-administration is documented to be associated with an increased risk of adverse effects, as documented for combined NSAIDs.

Q: Is it possible for Aspegic 1000 to interact with alcohol?

A: Yes, co-administration with alcohol (ethanol) is a restricted combination according to regulatory documents. This restriction is due to the documented increase in the risk of serious gastrointestinal hemorrhage (bleeding) when both substances are used together.

Q: Can older people use Aspegic 1000 safely?

A: Regulatory documents state that the use of this medicine requires particular caution in older individuals. This is due to an increased susceptibility to potential adverse effects in this age group. Official guidelines also specify a lower maximum daily dose for older adults to help manage potential risks.

Q: Are there specific instructions for dissolving the powder before taking it?

A: Yes, the official instructions indicate that the powder should be completely dissolved in a small quantity of liquid immediately prior to use. Suitable liquids listed in regulatory documents include water, milk, or fruit juice.

Q: Does Aspegic 1000 have any impact on kidney health?

A: Official information notes that its use is contraindicated in cases of severe renal (kidney) failure. Additionally, caution is required in patients with pre-existing mild to moderate kidney impairment, as NSAIDs are documented to potentially be associated with a deterioration of renal function.

Q: Is Aspegic 1000 meant for acute pain or ongoing conditions?

A: Regulatory guidelines generally limit the duration of use for pain and fever to a short period (e.g., 5 days for pain, 3 days for fever). This constraint indicates that the medicine is intended for short-term, symptomatic relief of temporary conditions rather than long-term, ongoing use.

Q: What are the most common or mild side effects people experience with Aspegic 1000?

A: The most commonly documented adverse events in official sources include gastrointestinal upset or irritation and an increased tendency for minor bleeding. Other mild effects reported may include headache or drowsiness.

Q: Do you have to take Aspegic 1000 with food?

A: Regulatory instructions permit dissolving the powder in milk or fruit juice, and authoritative guidance often suggests taking the active ingredient with food or milk. This practice is mentioned as a way to help minimize gastrointestinal irritation.

Q: Are there any common foods or drinks that should be avoided when using Aspegic 1000?

A: The only substance explicitly restricted by official documents due to increased risk of bleeding is alcohol (ethanol). No common foods are specifically listed as restricted in regulatory documentation for this medicine.

Q: Why is Aspegic 1000 packaged as a powder or granules?

A: Official product information describes the formulation as Lysine Acetylsalicylate, which is a highly soluble salt of the active drug. This specific chemical formulation is selected because it is best suited for rapid and complete dissolution when prepared as an oral solution.

Q: What if I forget to use Aspegic 1000 when I'm supposed to?

A: Official procedural restrictions state that a missed dose should not be recovered by taking a double dose. If the next scheduled dose is approaching, the prescribed schedule should be resumed by skipping the dose that was missed.

Q: Is there a warning about Aspegic 1000 causing ringing in the ears?

A: Yes, official and authoritative documents list tinnitus (ringing in the ears) as a potential symptom. This effect is generally associated with mild toxicity that may occur with higher than recommended plasma levels of the drug.

Q: Does taking Aspegic 1000 make you feel drowsy or affect driving?

A: Drowsiness is listed as a possible adverse effect in official documents. Caution should be exercised if the user experiences any adverse reactions, such as drowsiness, that may affect their ability to safely drive or operate machinery.

Q: Can Aspegic 1000 be used for period pain?

A: The medicine is officially indicated for the general symptomatic relief of pain, fever, and inflammation. This broad indication covers the symptomatic treatment of various aches and pains, which would include period pain (dysmenorrhea).

Q: What is the recommended storage temperature for Aspegic 1000 sachets?

A: Official storage requirements mandate that the product should not be stored above 25 C. The sachets should also be kept in the original package to ensure protection from moisture and environmental factors.

Q: Does Aspegic 1000 interact with anti-depressant medications?

A: Regulatory guidance advises caution when using this medicine with certain medications, such as Selective Serotonin-Reuptake Inhibitors (SSRIs). This is due to a documented potential for an increased risk of gastrointestinal bleeding or ulceration when these drug types are combined.

Q: Why are people talking about Aspegic 1000 and cardiovascular health online?

A: This discussion is related to the approved function of the active ingredient, Acetylsalicylic Acid (ASA). Its primary mechanism of inhibiting platelet aggregation is utilized in established therapeutic protocols for cardiovascular health, which is a key focus of regulatory information.

Q: Is it possible to have an allergic reaction to Aspegic 1000, and what are the signs?

A: Yes, official documents describe a risk of hypersensitivity (allergic) reactions. Signs of a severe reaction can include hives, difficulty breathing, and swelling of the face, lips, tongue, or throat. These reactions are classified in the official safety profile.

How should Aspegic 1000 be stored and disposed of?

How to Store and Dispose of Aspegic 1000?

The storage and disposal requirements for Aspegic 1000 are formally mandated to maintain product stability and ensure public safety.

Official Storage Requirements

Condition Type	Requirement
Temperature	Do not store above 25°C (Store below 25 C).
Packaging	Store in the original package.
Shelf-Life	3 years (When stored under required conditions).
Child Safety	Keep out of the sight and reach of children.

Disposal Instructions

Unused product or waste material must be disposed of in accordance with local requirements for pharmaceutical waste. Official guidance specifies that the release of pharmaceuticals in the environment should be minimized to prevent contamination. Do not dispose of the medication in household wastewater or general trash unless advised by a take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.